Last reviewed · How we verify
NCT05388682
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
trial testing Percutaneous transluminal pulmonary angioplasty in Takayasu Arteritis With Pulmonary Artery Involvement in 200 participants. Currently enrolling.
31 December 2042
Quick facts
| Lead sponsor | Chinese Pulmonary Vascular Disease Research Group |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 19 January 2014 |
| Primary completion | 31 December 2042 |
| Estimated completion | 31 December 2042 |
| Sites | 1 location across China |
Drugs / interventions tested
- Percutaneous transluminal pulmonary angioplasty
Conditions studied
- Takayasu Arteritis With Pulmonary Artery Involvement — all drugs for Takayasu Arteritis With Pulmonary Artery Involvement →
- Percutaneous Transluminal Pulmonary Angioplasty — all drugs for Percutaneous Transluminal Pulmonary Angioplasty →
- PAH Targeted Medication — all drugs for PAH Targeted Medication →
Sponsor
Chinese Pulmonary Vascular Disease Research Group
Who can join
Eligibility, any sex, with Takayasu Arteritis With Pulmonary Artery Involvement or Percutaneous Transluminal Pulmonary Angioplasty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05388682
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Takayasu Arteritis With Pulmonary Artery Involvement
Currently open trials in the same condition.
- NCT07184814 — Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement · recruiting
Other Chinese Pulmonary Vascular Disease Research Group trials
Trials by the same sponsor.
- NCT07481877 — Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study · not yet recruiting
- NCT05566002 — Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension · recruiting
- NCT05569655 — Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH · NA · unknown
- NCT05553015 — A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH) · unknown
- NCT05595200 — Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05388682 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Pulmonary Vascular Disease Research Group
- Last refreshed: 20 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05388682.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing